Uveal Melanoma

Uveal melanoma is the most common primary intraocular malignancy in adults, arising from melanocytes within the uveal tract of the eye. Despite being an eye tumor, it poses its greatest threat through metastasis — almost exclusively to the liver — which occurs in approximately 50% of patients and carries a median survival of under one year without treatment. The approval of tebentafusp (Kimmtrak) in 2022 marked the first FDA-approved therapy for this orphan cancer, opening a new chapter in its management.

Table of Contents

  1. What is Uveal Melanoma?
  2. Choroidal Nevus and Malignant Transformation
  3. Molecular Pathology: GNAQ/GNA11 and BAP1
  4. Unique Metastatic Pattern: The Liver
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment: Primary Tumor
  8. Treatment: Metastatic Uveal Melanoma
  9. Surveillance and Long-Term Follow-Up
  10. Key Research Papers
  11. PubMed Topic Searches
  12. Connections

1. What is Uveal Melanoma?

Uveal melanoma is a malignant tumor arising from melanocytes within the uveal tract — the vascular middle layer of the eye comprising the choroid, ciliary body, and iris. It is the most common primary intraocular malignancy in adults, with an incidence of approximately 5–7 per million per year in the United States, translating to roughly 2,000–2,500 new cases annually.

The uveal tract has three anatomically distinct components, and melanoma can arise in each:

A critically important distinction: uveal melanoma is biologically and molecularly distinct from cutaneous (skin) melanoma. They share the name "melanoma" because both arise from melanocytes, but they differ fundamentally in their driver mutations, metastatic patterns, response to therapy, and prognosis. BRAF mutations, which drive most cutaneous melanomas and are targeted by vemurafenib and dabrafenib, are largely absent in uveal melanoma. Immunotherapy response rates are far lower. This distinction is not merely academic — it has profound implications for treatment selection.

Risk Factors

Back to Table of Contents

2. Choroidal Nevus and Malignant Transformation

A choroidal nevus is a benign, flat or minimally elevated pigmented lesion of the choroid, analogous to a mole on the skin. Choroidal nevi are common — present in approximately 5–10% of the Caucasian adult population — and the vast majority remain benign throughout a patient's lifetime. However, some undergo malignant transformation into uveal melanoma, and distinguishing a stable benign nevus from a lesion at risk for transformation is one of the central challenges in ophthalmic oncology.

The annual risk of transformation of any given choroidal nevus into melanoma is approximately 1 in 8,845 (0.011%), making population-wide surveillance impractical. However, certain features of a nevus identify a subgroup at substantially higher risk, allowing targeted surveillance of those lesions.

The "TIFOSDS" Mnemonic for Malignant Transformation Risk

Shields et al. identified seven risk factors for malignant transformation of a choroidal nevus, captured in the mnemonic TIFOSDS (also taught as "To Find Small Ocular Melanoma Using Helpful Hints Daily"):

The number of risk factors present correlates with 5-year growth rates ranging from approximately 4% (0 risk factors) to over 50% (5 or more risk factors). Patients with two or more risk factors typically warrant surveillance every 6 months; those with zero risk factors may be monitored annually or less frequently.

The practical implication is that most choroidal nevi discovered incidentally — for example, on diabetic screening fundoscopy or routine eye exam — require only periodic photographic surveillance and are not cause for alarm. Education of patients about the very low absolute transformation risk while maintaining appropriate follow-up is an important aspect of clinical communication.

Back to Table of Contents

3. Molecular Pathology: GNAQ/GNA11 and BAP1

Uveal melanoma has a molecular landscape strikingly different from cutaneous melanoma. Understanding these driver alterations explains the tumor's unique biology, its resistance to BRAF-targeted therapies, and the logic behind emerging treatment approaches.

GNAQ and GNA11 Mutations (Early Driver Events)

The most common driver mutations in uveal melanoma occur in GNAQ and GNA11, genes encoding the alpha subunits of heterotrimeric G-proteins (Gq and G11). Approximately 85–90% of all uveal melanomas carry an activating point mutation in one of these genes — GNAQ Q209P or Q209L, or GNA11 Q209L being most frequent.

These mutations constitutively activate downstream signaling through the MEK/ERK (MAPK) and PI3K/AKT/mTOR pathways, driving uncontrolled melanocyte proliferation. Critically, GNAQ and GNA11 mutations are:

BAP1 and Chromosome 3 (Metastatic Risk Determinants)

BAP1 (BRCA1 Associated Protein 1) is a tumor suppressor gene located at chromosome 3p21.1. Its loss is the molecular hallmark of metastatic uveal melanoma, and it operates in the context of chromosome 3 copy number:

Additional Molecular Alterations

Beyond GNAQ/GNA11 and BAP1, several other recurrently mutated genes define molecular subgroups:

The clinical integration of molecular profiling — obtained via fine-needle aspiration biopsy (FNAB) at the time of primary tumor treatment — has transformed risk stratification and is now standard of care at major ocular oncology centers.

Back to Table of Contents

4. Unique Metastatic Pattern: The Liver

One of the most distinctive and clinically consequential features of uveal melanoma is the near-exclusive predilection for liver metastasis. Unlike cutaneous melanoma, which spreads to lung, brain, lymph nodes, bone, and other organs with roughly equal frequency, uveal melanoma metastasizes to the liver in 90–95% of cases, often with the liver as the sole site of disease for extended periods.

Biological Basis

The hepatic tropism of uveal melanoma is not fully understood but is thought to reflect a combination of factors:

Timing and Latency

A critical and underappreciated feature of uveal melanoma is the potential for very late metastasis. While the average time from primary diagnosis to detectable liver metastasis is 2–4 years, metastasis can occur 10, 15, or even 25 years after successful treatment of the primary tumor. This extended latency is thought to reflect immunologic control of dormant micrometastases that eventually escape surveillance.

The practical implication is profound: patients who have been treated for uveal melanoma — even those with low-risk molecular profiles — require lifelong annual liver surveillance. A patient free of disease 10 years after enucleation is not cured; they remain at risk indefinitely. This reality shapes the counseling and long-term care of every uveal melanoma patient.

Prognosis After Metastasis

Once liver metastases develop, prognosis historically has been grim. Before the approval of tebentafusp in 2022, median survival after diagnosis of metastatic uveal melanoma was approximately 12–14 months, with 1-year survival rates of roughly 50% and 5-year survival rates under 10%. The relative ineffectiveness of systemic immunotherapy (immune checkpoint inhibitors), which transformed outcomes in cutaneous melanoma, left metastatic uveal melanoma as one of oncology's most challenging unmet needs.

Back to Table of Contents

5. Clinical Presentation

The clinical presentation of uveal melanoma depends on the tumor's location, size, and extent at the time of diagnosis. Because choroidal melanoma — the most common form — originates in a posterior segment structure that patients cannot see or feel, many tumors are discovered before causing any symptoms at all.

Asymptomatic Discovery

A substantial proportion of uveal melanomas — estimates range from 30–50% — are found incidentally during routine fundoscopic examination, including:

This pattern of incidental detection has increased with wider use of fundus photography and widefield retinal imaging, and argues for systematic documentation and photographic surveillance of any pigmented fundus lesion.

Visual Symptoms

When symptoms do occur, they typically reflect the tumor's effects on adjacent retinal structures:

Anterior Segment Findings

Iris melanomas are the most visible subtype, presenting as a variably pigmented iris mass, often associated with iris heterochromia (color change) or distortion of the pupil. Ciliary body melanomas may cause a localized sector of dilated episcleral vessels ("sentinel vessels"), lens subluxation, or astigmatism from mass effect on the lens.

Fundoscopic Appearance

On indirect ophthalmoscopy or fundus photography, a choroidal melanoma typically appears as:

Metastatic Symptoms

At the time of initial ocular diagnosis, systemic metastases are present in only 2–4% of patients (subclinical micrometastases are far more common). When hepatic metastases become symptomatic, patients may experience right upper quadrant (RUQ) pain or discomfort, fatigue, unintentional weight loss, early satiety, and eventually jaundice in advanced disease.

Back to Table of Contents

6. Diagnosis

Uveal melanoma is predominantly a clinical diagnosis supported by multimodal imaging. Tissue biopsy was historically avoided to minimize risk of extraocular dissemination, but fine-needle aspiration biopsy has become standard practice at specialized centers for molecular prognostication.

Ocular Ultrasound (B-scan)

B-scan ultrasonography is the cornerstone of uveal melanoma diagnosis and staging. Key features include:

Fundus Fluorescein Angiography (FFA) and Indocyanine Green (ICG) Angiography

FFA reveals the tumor's intrinsic vascularity ("double circulation"), areas of leakage, and associated retinal changes. ICG angiography provides better visualization of deep choroidal vessels and can highlight the tumor's vascular supply in heavily pigmented lesions.

Optical Coherence Tomography (OCT)

OCT demonstrates subretinal fluid, photoreceptor disruption, retinal pigment epithelium (RPE) changes, and the status of the overlying retina — information that guides visual prognosis after treatment and helps distinguish melanoma from choroidal nevi or hemangiomas.

MRI Orbit

MRI provides superior soft tissue characterization compared to ultrasound, particularly for detecting extraocular extension through the sclera — a high-risk finding that significantly worsens prognosis and may alter surgical planning. On T1-weighted MRI, melanotic melanomas typically appear hyperintense (bright) relative to vitreous, reflecting the paramagnetic properties of melanin.

Fine-Needle Aspiration Biopsy (FNAB)

FNAB via a trans-scleral or trans-vitreal approach allows collection of tumor cells for:

Systemic Staging

All patients with confirmed uveal melanoma require baseline systemic staging to exclude overt metastatic disease:

Back to Table of Contents

7. Treatment: Primary Tumor

The goal of primary treatment for uveal melanoma is local tumor control — eliminating the tumor to prevent local recurrence and potential local dissemination — while preserving as much vision as possible. Importantly, studies (most notably the Collaborative Ocular Melanoma Study, COMS) have established that choice of primary treatment modality does not affect overall survival; patients who receive plaque brachytherapy survive no differently than those who undergo enucleation. This landmark finding shifted the treatment philosophy from "save the patient's life" toward "save the patient's eye and vision."

Plaque Brachytherapy (Most Common)

Episcleral plaque brachytherapy — surgically sewing a radioactive plaque (containing either iodine-125 or ruthenium-106) to the outer surface of the eye over the tumor — is the most widely used eye-conserving treatment worldwide. Key features:

Proton Beam Radiotherapy (PBR)

Charged particle therapy (proton or helium ions) delivers a highly conformal radiation dose with minimal exit dose beyond the target, enabled by the Bragg peak phenomenon. Advantages over plaque brachytherapy:

Enucleation (Surgical Removal of the Eye)

Enucleation remains indicated for:

Following the COMS trial results, enucleation is no longer recommended over radiotherapy for medium tumors out of any hope of survival benefit — the decision is made on anatomic and quality-of-life grounds.

Trans-Pupillary Thermotherapy (TTT)

Infrared laser hyperthermia (TTT) can be used as monotherapy for small, thin (<3 mm) choroidal melanomas with favorable features, or as an adjunct to plaque brachytherapy to boost the anterior tumor margin. It is not appropriate for thicker or larger tumors.

Observation

Very small, indeterminate pigmented lesions with multiple low-risk features (absence of orange pigment, no subretinal fluid, no symptoms, stable on serial photography) may be monitored with periodic fundus examination and photography every 3–6 months. Once growth is documented, treatment is initiated promptly.

Back to Table of Contents

8. Treatment: Metastatic Uveal Melanoma

Metastatic uveal melanoma has historically been among the most treatment-refractory malignancies in oncology. The tumor's low tumor mutational burden (TMB) — a consequence of driver mutations in G-protein signaling rather than UV-induced mutational damage — makes it poorly immunogenic and largely resistant to immune checkpoint inhibitors that have transformed metastatic cutaneous melanoma.

Tebentafusp (Kimmtrak) — First FDA-Approved Therapy

The approval of tebentafusp (formerly IMCgp100) by the FDA in January 2022 represented a watershed moment for uveal melanoma. It is the first therapy ever to improve overall survival in metastatic uveal melanoma in a randomized phase 3 trial, and the first approved T-cell receptor (TCR)-based bispecific therapy in oncology.

Liver-Directed Therapies

Because the liver is the predominant and often sole site of metastatic disease, liver-directed therapies deliver high local drug concentrations while minimizing systemic toxicity:

Immune Checkpoint Inhibitors

PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab) and CTLA-4 inhibitors (ipilimumab) show markedly reduced efficacy in uveal melanoma compared to cutaneous melanoma, reflecting the tumor's low TMB and relative immune exclusion:

MEK Inhibitors and Targeted Agents

Given the near-universal presence of GNAQ/GNA11 mutations and downstream MEK/ERK activation, MEK inhibitors (selumetinib, trametinib) have been extensively studied. Single-agent MEK inhibition demonstrates only modest efficacy (disease stabilization more than objective response), and combinations with PKC inhibitors and other agents targeting the GNAQ/GNA11 signaling cascade are under active investigation.

Tumor-Infiltrating Lymphocyte (TIL) Therapy

Adoptive cell transfer using expanded autologous TILs from uveal melanoma hepatic metastases is in clinical trials. Preliminary data suggest activity in a subset of patients, and this approach may complement tebentafusp in the future. The hepatic metastases of uveal melanoma — despite the tumor's relative immune exclusion — contain populations of tumor-reactive T cells that can be expanded ex vivo.

Back to Table of Contents

9. Surveillance and Long-Term Follow-Up

Because uveal melanoma can metastasize years to decades after primary treatment, lifelong surveillance is mandatory for all patients regardless of prognostic risk category. The objectives are to detect hepatic (and occasionally extrahepatic) metastasis early enough to permit intervention, and to monitor the treated eye for local recurrence, radiation complications, and treatment side effects.

Risk-Stratified Surveillance Protocols

The intensity of surveillance is informed by the tumor's molecular profile:

Ocular Follow-Up

Following primary treatment, the treated eye is monitored by the treating ophthalmologist for:

Patient Education and Psychosocial Support

The prospect of lifelong surveillance and the risk of late metastasis impose a significant psychosocial burden on uveal melanoma survivors. Many patients experience anxiety at each surveillance interval ("scanxiety"), and the fact that metastasis can occur decades after what appears to have been successful treatment is difficult to communicate and to live with. Connecting patients with disease-specific advocacy organizations (such as the Ocular Melanoma Foundation and Cure UM) and peer support groups is an integral part of long-term care.

Back to Table of Contents

10. Key Research Papers

  1. Onken MD et al. "Oncogenic mutations in GNAQ occur early in uveal melanoma." Invest Ophthalmol Vis Sci. 2008;49(12):5230–4. PMID 18586879
  2. Nathan P et al. "Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma." N Engl J Med. 2021;385(13):1196–1206. PMID 34551229
  3. Harbour JW et al. "Frequent mutation of BAP1 in metastasizing uveal melanomas." Science. 2010;330(6009):1410–3. PMID 21051595
  4. Coupland SE et al. "Uveal melanoma." Lancet. 2008;372(9633):114–21. PMID 18620951
  5. Collaborative Ocular Melanoma Study Group. "The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma." Arch Ophthalmol. 2006;124(12):1684–93. PMID 17159027
  6. Singh AD et al. "Uveal melanoma: trends in incidence, treatment, and survival." Ophthalmology. 2011;118(9):1881–5. PMID 21621831
  7. Diener-West M et al. "Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma." Arch Ophthalmol. 2005;123(12):1639–43. PMID 16344438
  8. Shields CL et al. "Choroidal nevus transformation into melanoma." Arch Ophthalmol. 2009;127(8):981–7. PMID 19667334
  9. Yoo SY et al. "Percutaneous hepatic perfusion (chemosaturation) with melphalan for unresectable hepatic metastases from uveal melanoma." J Vasc Interv Radiol. 2015;26(4):523–32. PMID 25661025
  10. Johansson P et al. "Fine-needle aspiration biopsy with chromosomal analysis of uveal melanoma." Acta Ophthalmol. 2010;88(5):521–4. PMID 19900213
  11. Ewens KG et al. "Genomic profile of 320 uveal melanoma cases." Genes Chromosomes Cancer. 2013;52(7):683–97. PMID 23606267
  12. van Raamsdonk CD et al. "Mutations in GNA11 in uveal melanoma." N Engl J Med. 2010;363(23):2191–9. PMID 21083380

Back to Table of Contents

PubMed Topic Searches

  1. Uveal melanoma treatment
  2. Choroidal melanoma brachytherapy
  3. Uveal melanoma liver metastasis
  4. GNAQ GNA11 uveal melanoma
  5. BAP1 monosomy 3 uveal melanoma prognosis
  6. Tebentafusp uveal melanoma
  7. Percutaneous hepatic perfusion uveal melanoma
  8. Choroidal nevus malignant transformation

Back to Table of Contents

Connections

Back to Table of Contents